Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

polyneuropathy - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

polyneuropathy

MONDO:0001824

Find Clinical TrialsTrials

Overview

A disease or disorder affecting more than one nerve.

Treatments2 FDA approved

Clinical Trials83 registered · 45 recruiting

Diagnosis

Biomarker and diagnostic research for polyneuropathy has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for polyneuropathy, including PATISIRAN (ONPATTRO, approved 2018) and EPLONTERSEN (WAINUA, approved 2023).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

83 clinical trials registered, 45 recruiting. Interventions under study include other interventions, drug therapy, biologic therapy, and medical devices. Pipeline includes 4 PHASE4, 12 PHASE3, 12 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07273903](https://clinicaltrials.gov/study/NCT07273903)

Data assembled from 4 of 12 sources · Last updated Oct 3, 2026, 6:20 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of ONPATTRO for managing polyneuropathy?
→Are any of the 83 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	63	22%
Patient case studies	57	20%
Disease patterns and progression	53	18%
Clinical study results	51	18%
Testing and diagnosis research	31	11%
Laboratory research	19	7%
New treatment approaches	9	3%
Other research	8	3%

Kisho

polyneuropathy

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Disease modifying treatment of hereditary transthyretin amyloidosis with polyneuropathy in Germany - expert consensus of the German society of amyloid diseases (DGAK) and the German neurological society (DGN).

ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world cases.

Severe polyneuropathy in HIV-negative human herpesvirus 8-associated multicentric Castleman disease successfully treated with rituximab and liposomal doxorubicin.

polyneuropathy

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Disease modifying treatment of hereditary transthyretin amyloidosis with polyneuropathy in Germany - expert consensus of the German society of amyloid diseases (DGAK) and the German neurological society (DGN).

ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world cases.

Severe polyneuropathy in HIV-negative human herpesvirus 8-associated multicentric Castleman disease successfully treated with rituximab and liposomal doxorubicin.